USE OF PHOSPHONATE NUCLEOTIDE ANALOGUE FOR TREATING HEPATITIS B VIRUS INFECTIONS

摘要

Provided are pharmaceutically acceptable compositions comprising 2-amino-9-[2-[bis(2,2,2-trifluoroethoxy) phosphonylmethoxy]ethyl]-6-(4-methoxyphenylthio) purine (LY582563) for oral administration to treat hepatitis B virus infections in infected patients. The compositions are in unit dosage form including, per unit dosage, about 2.5 to about 20 mg of the purine. The compositions are adapted for oral administration, preferably in the form of a tablet or capsule, and can be administered in single or multiple doses, provided that the total daily dose of the purine is in the range of from about 2.5 mg to about 20 mg per patient per day. These compositions are particularly advantageous for lowering the plasma HBV DNA levels, or ameliorating symptoms, conditions, or disorders caused by hepatitis B virus, of human patients with chronic HBV infection.